Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CPN1 | P15169 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8588247 | 1.00 | CYP2C19 (0.50) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| SCHEMBL6478880 | 0.94 | TBXAS1 (0.51) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| SCHEMBL8584497 | 0.94 | TBXAS1 (0.51) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| SCHEMBL28581228 | 0.93 | TBXAS1 (0.54) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| SCHEMBL4086184 | 0.88 | CYP2C19 (0.53) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| SCHEMBL8582632 | 0.88 | CYP2C19 (0.53) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| SCHEMBL14360139 | 0.86 | TBXAS1 (0.60) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| Ammonia Solution, Strong SCHEMBL28562956 | 0.84 | TBXAS1 (0.59) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| Ammonia Solution, Strong SCHEMBL28556745 | 0.84 | TBXAS1 (0.59) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| SCHEMBL30371912 | 0.83 | CYP2C19 (0.61) | CYP2C19TBXAS1CYP2D6SRCPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0603229-B1 | QUINUCLIDINE ESTERS PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER LTD (GB) | 1998-06-10 | — | — | EP | disclosed |
| CN-1037269-C | Therapeutic compounds | PFIZER (US) | 1998-02-04 | — | — | CN | disclosed |
| US-5543419-A | TREATING CHRONIC OBSTRUCTIVE AIRWAYS DISEASE OR ASTHMA; ANTIMUSCARINIC BRONCHODILATOR AGENTS | PFIZER INC (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0603229-A1 | QUINUCLIDINE ESTERS PROCESS AND INTERMEDIATE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pfizer Limited (GB) | 1994-06-29 | — | — | EP | disclosed |
| CN-1070911-A | The treatment compound | PFIZER (US) | 1993-04-14 | — | — | CN | disclosed |
| WO-1993006098-A1 | QUINUCLIDINE ESTERS PROCESS AND INTERMEDIATE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER LIMITED (GB) | 1993-04-01 | — | — | WO | disclosed |